Evidence map›Paper›PMID 33926295›Full record

ReviewThe Journal of international medical research2021

Paraneoplastic immunoglobulin A nephropathy in a patient with lung adenocarcinoma: A case report and literature review.

Jing Wang, Yang Liu, Nian Liu, Menghan Gao, Hang Yuan

Abstract readCase ReportsReview
In one paragraph

Review in The Journal of international medical research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Metastatic Non-Small-Cell Lung Cancer Presenting as Renal Failure From IgA Nephropathy.Journal of investigative medicine high impact case reports
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jing WangDepartment of Nephrology, The First Hospital of Jilin University, Changchun, Jilin Province, China.ORCID https://orcid.org/0000-0002-3715-1174
Yang LiuDepartment of Nephrology, The First Hospital of Jilin University, Changchun, Jilin Province, China.
Nian LiuDepartment of Urology, The First Hospital of Jilin University, Changchun, Jilin Province, China.
Menghan GaoDepartment of Nephrology, The First Hospital of Jilin University, Changchun, Jilin Province, China.
Hang YuanDepartment of Nephrology, The First Hospital of Jilin University, Changchun, Jilin Province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunoglobulin A nephropathy (lgAN) is a common primary glomerulonephritis, but paraneoplastic IgAN has been rarely reported. This current case report describes a 49-year-old male patient that was referred with proteinuria, oedema and hypoproteinaemia after lung cancer surgery and before the first cycle of chemotherapy. Renal biopsy confirmed lgAN. The patient received four cycles of chemotherapy (first cycle: pemetrexed + nedaplatin; second to fourth cycle: pemetrexed + carboplatin). The symptoms of IgAN were gradually relieved with additional cycles of chemotherapy. At the latest follow-up on 10 February 2020, there was no evidence of lung cancer recurrence and all symptoms of lgAN had disappeared. lgAN combined with lung adenocarcinoma is quite rare, which suggests that IgAN might be a paraneoplastic manifestation of lung adenocarcinoma.

Indexed as

Adenocarcinoma of LungGlomerulonephritis, IGALung NeoplasmsHumansMaleMiddle AgedNeoplasm Recurrence, LocalProteinuriacase reportChemotherapyimmunoglobulin A nephropathylung adenocarcinomanephrotic syndromeproteinuria

Identifiers

PMID33926295
PMCPMC8113932

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.